drugset / Trial / NCT01305109

A Phase III Clinical Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E

NCT01305109

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The trial is a phase III randomized, double-blind, placebo-controlled trial with the primary objective of evaluating the efficacy of three doses of ORV 116E, 10\^5.0 FFU, against severe rotavirus gastroenteritis, in comparison with a placebo in India.

Timeline

Start
2011-03
Primary completion
2013-12
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject ROTAVAC® Vaccine 0.5 ml Oral
Subject ROTAVAC® Vaccine 100000 unknown Oral

Indications